Total (n = 276) | Age | |||
---|---|---|---|---|
0–5 years (n = 22) | 6–11 years (n = 43) | 12–18 years (n = 211) | ||
Age, years | ||||
Median [Quartile] | 15.0 [12.0, 17.0] | 3.5 [2.0, 4.0] | 9.0 [8.0, 11.0] | 16.0 [14.0, 17.0] |
Sex, n (%) | ||||
Male | 209 (75.7) | 10 (45.5) | 23 (53.5) | 176 (83.4) |
Female | 67 (24.3) | 12 (54.5) | 20 (46.5) | 35 (16.6) |
Comorbidity, n (%) | ||||
Kidney disease | 96 (34.8) | 6 (27.3) | 14 (32.6) | 76 (36.0) |
Cardiovascular disease | 63 (22.8) | 9 (40.9) | 15 (34.9) | 39 (18.5) |
Metabolic syndrome | 118 (42.8) | 5 (22.7) | 20 (46.5) | 93 (44.1) |
Down syndrome | 15 (5.4) | 2 (9.1) | 3 (7.0) | 10 (4.7) |
Treatment and drug use, n (%) | ||||
Cardiovascular disease drug | 9 (3.3) | 0 (0.0) | 5 (11.6) | 4 (1.9) |
Diuretic drug | 13 (4.7) | 2 (9.1) | 4 (9.3) | 7 (3.3) |
β blocker | 7 (2.5) | 1 (4.5) | 2 (4.7) | 4 (1.9) |
Ca antagonist | 8 (2.9) | 0 (0.0) | 1 (2.3) | 7 (3.3) |
ACE inhibitor and/or ARB | 32 (11.6) | 1 (4.5) | 6 (14.0) | 25 (11.8) |
Antihyperlipidemic drug | 14 (5.1) | 0 (0.0) | 0 (0.0) | 14 (6.6) |
Antidiabetic drug | 5 (1.8) | 0 (0.0) | 0 (0.0) | 5 (2.4) |
Immunosuppressant | 18 (6.5) | 1 (4.5) | 7 (16.3) | 10 (4.7) |
Vitamin D | 13 (4.7) | 0 (0.0) | 3 (7.0) | 10 (4.7) |
Dialysis | 2 (0.7) | 0 (0.0) | 0 (0.0) | 2 (0.9) |
Treatment with uric acid lowering drug, n (%) | 97 (35.1) | 1 (4.5) | 10 (23.3) | 86 (40.8) |
Number of measurement of sUA | ||||
Median [Quartile] | 2.0 [1.0, 4.0] | 1.0 [0.0, 3.0] | 3.0 [1.0, 6.0] | 2.0 [1.0, 5.0] |
Size of the facility, n (%) | ||||
0–19 beds | 113 (40.9) | 3 (13.6) | 11 (25.6) | 99 (46.9) |
20–99 beds | 6 (2.2) | 1 (4.5) | 0 (0.0) | 5 (2.4) |
100–299 beds | 31 (11.2) | 2 (9.1) | 4 (9.3) | 25 (11.8) |
≥ 300 beds | 131 (47.5) | 16 (72.7) | 28 (65.1) | 87 (41.2) |